Enzo Biochem (ENZ) Getting Somewhat Positive Press Coverage, Analysis Finds

News stories about Enzo Biochem (NYSE:ENZ) have been trending somewhat positive on Sunday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzo Biochem earned a news impact score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 43.6557449695819 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

ENZ has been the subject of several recent research reports. BidaskClub downgraded shares of Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. TheStreet downgraded shares of Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th. Finally, Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th.

Shares of Enzo Biochem (NYSE:ENZ) traded down $0.28 on Friday, reaching $9.53. The company had a trading volume of 100,100 shares, compared to its average volume of 203,713. Enzo Biochem has a 52-week low of $6.27 and a 52-week high of $12.04.

In related news, EVP James Michael O’brien sold 22,866 shares of Enzo Biochem stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $10.28, for a total transaction of $235,062.48. Following the sale, the executive vice president now directly owns 34,886 shares in the company, valued at $358,628.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Elazar Rabbani sold 72,401 shares of Enzo Biochem stock in a transaction dated Wednesday, October 25th. The shares were sold at an average price of $10.09, for a total transaction of $730,526.09. Following the sale, the chief executive officer now owns 2,038,474 shares in the company, valued at $20,568,202.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 191,398 shares of company stock worth $1,925,292. Company insiders own 9.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Enzo Biochem (ENZ) Getting Somewhat Positive Press Coverage, Analysis Finds” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/enzo-biochem-enz-getting-somewhat-positive-press-coverage-analysis-finds.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Insider Buying and Selling by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply